Skip to main navigation

Contact Us

Investor Relations

Our Company
Product Candidates
- Pipeline
- MultiTAA Therapies
Our Science
Clinical Trials
- Active Clinical Trials
- Expanded Access Policy
Investors/Media
Careers

Investors/Media

Press Releases

Press Releases

Year

May 08, 2023

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

May 01, 2023

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

Mar 22, 2023

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Dec 13, 2022

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Nov 22, 2022

Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer

Nov 10, 2022

Marker Therapeutics Reports Q3 2022 Operating and Financial Results

Sep 13, 2022

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Sep 08, 2022

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Aug 11, 2022

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

Aug 04, 2022

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 21 - 30 of 103

Investors/Media

Investors/Media Home
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials & Filings
Corporate Governance
Investor Resources

IR and Media Contacts

investor.relations@markertherapeutics.com
(713) 400-6400

©2024 Marker Therapeutics, Inc. All Rights Reserved.

Footer Links

Sitemap
Terms of Use
Privacy Policy